Context Capital Management LLC Makes New $7.43 Million Investment in Drugs Made In America Acquisition II Corp. $DMII

Context Capital Management LLC acquired a new stake in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 750,000 shares of the company’s stock, valued at approximately $7,425,000.

Other large investors have also modified their holdings of the company. Geode Capital Management LLC purchased a new stake in Drugs Made In America Acquisition II in the fourth quarter valued at approximately $265,000. ABC Arbitrage SA acquired a new position in Drugs Made In America Acquisition II in the fourth quarter valued at $396,000. Deltec Asset Management LLC purchased a new stake in Drugs Made In America Acquisition II during the fourth quarter valued at about $495,000. Quarry LP purchased a new stake in Drugs Made In America Acquisition II during the fourth quarter valued at about $990,000. Finally, DLD Asset Management LP acquired a new stake in Drugs Made In America Acquisition II during the fourth quarter worth about $1,111,000.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on DMII. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Drugs Made In America Acquisition II in a research note on Friday, May 29th. Wall Street Zen raised shares of Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Drugs Made In America Acquisition II has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Stock Up 0.0%

Shares of DMII stock opened at $10.09 on Friday. The business’s fifty day moving average is $10.03. Drugs Made In America Acquisition II Corp. has a 1-year low of $9.86 and a 1-year high of $10.09.

About Drugs Made In America Acquisition II

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.